Here’s the notice in Cancer Immunology, Immunotherapy for “Immunotherapy of metastatic colorectal cancer with vitamin D-binding protein-derived macrophage-activating factor, GcMAF:”
This article has been retracted by the Journal’s Editors-in-Chief in conjunction with the Publisher (Springer) due to irregularities in the Institutional Review Board documentation.
The paper has been cited 28 times, according to Thomson Scientific’s Web of Knowledge.
As we wrote in another post about Nobutu Yamamoto’s work, we’ve
noticed that retractions for IRB documentation problems are often a bit like jailing Al Capone on tax evasion: They’re the easiest charges to prove, but they’re likely the least of a study’s problems.
A website, GcMAF.eu, continues to hawk the results of treatment:
The results from all the diseases we list are astonishing, but in late stage cancer the clinics achieve an average of 25% tumour reduction per week. (We get that reduction with pancreatic cancer too.)